Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
Managing patients with plasma cell neoplasms, diseases in which abnormal plasma cells or myeloma cells form tumors in the bones or soft tissues of the body, poses numerous challenges for clinicians. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts discussed evidenced-based approaches for the treatment of patients with these diseases. Moderated by Dr. Andrew D. Zelenetz, the session focused on patients with transplant-ineligible newly diagnosed multiple myeloma, active multiple myeloma, and light chain amyloidosis.
Disclosures: Dr. Zelenetz has disclosed that he received consulting fees from AbbVie, Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, Novartis Pharmaceuticals Corporation, Adaptive Biotechnologies Corporation, Genentech, Inc./Roche Laboratories, Inc., and Pharmacyclics; is a scientific advisor for AbbVie, Inc., AstraZeneca Pharmaceuticals LP, and MorphoSys AG; and receives grant/research support from BeiGene, Gilead Sciences, Inc., MEI Pharma Inc., and Roche Laboratories, Inc. Dr. Baljevic has disclosed that he received consulting fees from Cardinal Health and Takeda Pharmaceuticals North America, Inc., and served as an internal review committee member for Karyopharm Therapeutics and a scientific advisor for Takeda Pharmaceuticals North America, Inc. Dr. Efebera has disclosed that she has received honoraria from Janssen Pharmaceutica Products, LP, and Takeda Pharmaceuticals North America, Inc, and is a scientific advisor for Akcea Therapeutics. Dr. Green has disclosed that he has no financial interests, arrangement, affiliations, or commercial interests with any manufacturers of any products discussed in this article or their competitors. Dr. Liedtke has disclosed that she receives grant/research support from Agios, Inc., Amgen Inc., Celator Pharmaceuticals, Celgene Corporation, Genentech, Inc., Gilead Sciences, Inc., Janssen Pharmaceutica Products, LP, bluebird bio, Inc., Prothena, Pfizer Inc., and Takeda Pharmaceuticals North America, Inc; received consulting fees from Amgen Inc.; and is a scientific advisor for Celgene Corporation, Janssen Pharmaceutica Products, LP, and Jazz Pharmaceuticals Inc. Dr. Shah has disclosed that she receives grant/research support from Celgene Corporation, Janssen Pharmaceutica Products, LP, bluebird bio, Inc., Sutro Biopharma; is a scientific advisor for Genentech, Inc., Seattle Genetics, Oncopeptides, Karoypharm, Surface Oncology, Precision Biosciences, Glaxo Smith Kline, Nektar, Amgen, Indapta Therapeutics, and Sanofi; and owns stock in Indapta Therapeutics.
© 2019-2024 National Comprehensive Cancer Network